Anthony Rostain, professor of psychiatry and pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and attending and supervising psychiatrist at the Children’s Hospital of Pennsylvania and the University of Pennsylvania Health System. “This study reminds us that we need to keep a close watch on our patients and follow up on any suspicious changes in mood, thinking or behavior,” says Dr. In other words, psychosis occurred in 1 out of every 660 patients, and the risk for psychosis was nearly twice as high among patients taking amphetamine for the first time compared to those taking methylphenidate for the first time. Among those, 237 psychosis diagnoses came from the group taking amphetamine and 106 came from the group taking methylphenidate. The participants were evenly split between those who had started taking amphetamine and those who took methylphenidate for the first time between January 1, 2004, and September 30, 2015.Īmong this population, there were 343 new diagnoses of psychosis that merited a prescription for an antipsychotic medication within the first four to five months of stimulant-medication treatment.
The studied population included 221,846 adolescents and young adults ages 13-25 who received a stimulant prescription for ADHD. Though the chance of developing psychosis - including depressive disorder or bipolar disorder with psychotic features, schizophrenia spectrum disorders, delusional disorder, hallucinations, and unspecified psychosis - is low overall, patients taking amphetamine are twice as likely as patients taking methylphenidate to merit a diagnosis. A study published in The New England Journal of Medicine 1 finds that young patients with attention deficit disorder ( ADHD or ADD) beginning a first-time amphetamine, like Adderall or Vyvanse, are more likely to develop psychosis than are similar patients starting methylphenidate, like Ritalin or Concerta.
0 kommentar(er)
